NTRK2 and Parkinson disease: Recent observations in an in vivo study showed that 7,8-DHF administration led to the activation of TrkB signaling, reductions in α-Syn and tau phosphorylation, protection of DA neurons, and improvements of behavioral deficits in a rotenone-induced rat model of PD, suggesting that 7,8-DHF may be a useful agent in PD therapy [36].